Saroglitazar Reduced Liver Fat and Fibrosis in Metabolic Dysfunction Associated Steatotic Liver Disease: A Case Report
Published: 2024-07-09
Page: 93-97
Issue: 2024 - Volume 7 [Issue 1]
Rajesh R. Kulkarni *
Raghavendra Clinic, Darbar galli, Belagavi – 590 001, Karnataka, India.
*Author to whom correspondence should be addressed.
Abstract
Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is revised nomenclature of Non-alcoholic fatty liver disease (NAFLD) which is very commonly prevalent condition in India. Currently only one drug Saroglitazar is approved for treatment of NAFLD in India. It is a dual peroxisome proliferator-activated receptor (PPAR α/γ) agonist which improves insulin sensitivity and reduce triglyceride along with liver fat and fibrosis in NAFLD cases. In this case study, MASLD patient was prescribed Saroglitazar 4 mg once daily along with existing anti-diabetic and lipid lowering therapy and at 24 weeks; Saroglitazar had shown significant improvement in glycemic, lipid and transient elastography parameters.
Keywords: Liver fat, liver fibrosis, fatty liver disease, metabolic dysfunction